Agonizing Over Treg Expansion to Treat Human Disease: An Update on Our TNFRSF25-Agonist, PTX-35

Time: 4:30 pm
day: Day One | Track B | Afternoon


  • Describing a clinical-stage Treg immunomodulator with utility in both oncology and auto/inflammation
  • Demonstrating preclinical efficacy in several indications including transplantation, autoimmunity, and metabolic diseases
  • Expanding plans for new indications & modalities – opportunities for partnerships